Pages that link to "Q39525906"
Jump to navigation
Jump to search
The following pages link to Clonidine and the treatment of the opiate withdrawal syndrome (Q39525906):
Displaying 50 items.
- Alpha2-adrenergic agonists for the management of opioid withdrawal (Q24185795) (← links)
- Alpha2-adrenergic agonists for the management of opioid withdrawal (Q24197769) (← links)
- Opioid antagonists with minimal sedation for opioid withdrawal (Q24240041) (← links)
- Buprenorphine for the management of opioid withdrawal (Q24240149) (← links)
- Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal (Q24240954) (← links)
- Alpha 2 -adrenergic agonists for the management of opioid withdrawal (Q24241305) (← links)
- Opioid antagonists with minimal sedation for opioid withdrawal (Q24244653) (← links)
- Alpha2 adrenergic agonists for the management of opioid withdrawal (Q24245988) (← links)
- Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal (Q24246081) (← links)
- Buprenorphine for the management of opioid withdrawal (Q24246088) (← links)
- Biological significance of agmatine, an endogenous ligand at imidazoline binding sites (Q24673628) (← links)
- Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence (Q26865674) (← links)
- Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal (Q27000762) (← links)
- Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status (Q28280398) (← links)
- Corticotropin-releasing factor (CRF) and α 2 adrenergic receptors mediate heroin withdrawal-potentiated startle in rats (Q30431860) (← links)
- Alcohol and drug abuse in trauma (Q31857522) (← links)
- Opioid dependence treatment: options in pharmacotherapy (Q33868638) (← links)
- Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience (Q34081656) (← links)
- Alpha2-adrenergic agonists in opioid withdrawal (Q34564590) (← links)
- Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes? (Q34613312) (← links)
- Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice (Q34973799) (← links)
- Marijuana withdrawal syndrome in the animal model (Q34986723) (← links)
- Dealing with sadness, madness and hostility. New psychotropic drug remedies for the future (Q35530687) (← links)
- The narcotic bowel syndrome: clinical features, pathophysiology, and management (Q36136622) (← links)
- The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal. (Q36626505) (← links)
- A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal (Q37036723) (← links)
- Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence (Q37405260) (← links)
- Comparison of the efficacy of buprenorphine and clonidine in detoxification of opioid-dependents (Q37527538) (← links)
- The pharmacological treatment of opioid addiction--a clinical perspective (Q37695153) (← links)
- Advancing addiction treatment: what can we learn from animal studies? (Q38092089) (← links)
- Pharmacotherapies for treating opioid use disorder (Q38096571) (← links)
- Diagnosis and treatment of narcotic bowel syndrome (Q38206072) (← links)
- The narcotic bowel syndrome: a recent update (Q38248064) (← links)
- Buprenorphine for managing opioid withdrawal (Q38950890) (← links)
- Managing illicit drug use. A practical guide (Q40389370) (← links)
- Opiate withdrawal (Q40582985) (← links)
- Sulphatoxymelatonin excretion during opiate withdrawal: a preliminary study (Q40638593) (← links)
- Are detoxification programmes effective? (Q40933216) (← links)
- Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment. (Q41201027) (← links)
- Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. (Q42541323) (← links)
- Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal (Q42546661) (← links)
- Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response (Q43601604) (← links)
- Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine (Q43648910) (← links)
- Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone (Q44049012) (← links)
- Prolonged activation of mesolimbic dopaminergic neurons by morphine withdrawal following clonidine: participation of imidazoline and norepinephrine receptors. (Q44407129) (← links)
- Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis (Q46343519) (← links)
- Effect of adenosine analogues on the expression of opiate withdrawal in rats (Q47569719) (← links)
- Clonidine attenuates morphine withdrawal and subsequent drug sensitization in rhesus monkeys (Q48613080) (← links)
- The impact of naloxone/lofexidine combination treatment on the opiate withdrawal syndrome. (Q52279689) (← links)
- Lofexidine for opiate detoxification. (Q52309012) (← links)